Patents Assigned to Institut National de la Sante et de la Recherche
-
Patent number: 11821044Abstract: The present invention relates to methods for screening a subject for a cancer. In particular, the present invention relates to a method (A) for screening a subject for a cancer comprising the steps of i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining the total concentration of mitochondrial cell free nucleic acids, ii) determining the total concentration of nuclear cell free nucleic acids iv) calculating the ratio of the level determined at step ii) to the concentration determined at step iii), v) comparing ratio determined at step iv) with a predetermined corresponding reference value and vi) concluding that the subject suffers from a cancer when the ratio determined at step iv) is lower than the predetermined corresponding reference value or concluding that the subject does not suffer from a cancer when the ratio determined at step iv) is higher than the predetermined corresponding reference value.Type: GrantFiled: June 23, 2020Date of Patent: November 21, 2023Assignees: INSTITUT NATIONAL DE LA SANTÈ ET DE LA RECHERCHE MÈDICALE, INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIERInventors: Alain Thierry, Safia El Messaoudi
-
Publication number: 20230364232Abstract: An immunogenic product including at least one immunoglobulin or fragment thereof conjugated with a carrier protein, wherein the at least one immunoglobulin is IgE and preferably wherein the IgE fragment includes the IgE C?3 domain, and wherein the carrier protein is preferably CRM197. Also the use of this immunogenic product for treating inflammatory disorders, and in particular allergic disorders.Type: ApplicationFiled: September 17, 2021Publication date: November 16, 2023Applicants: NEOVACS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEURInventors: Laurent REBER, Pierre BRUHNS, Eva CONDE GARCIA, Marija BACKOVIC, Vincent SERRA, Géraldine GROUARD-VOGEL, Romain BERTRAND
-
Patent number: 11814654Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.Type: GrantFiled: June 19, 2020Date of Patent: November 14, 2023Assignees: Institut National de la Sante et de la Recherche Medicale, Université Paul Sabatier Toulouse IIIInventor: Elvire Gouze
-
Patent number: 11814685Abstract: This invention relates to a method for diagnosing and/or prognosticating HER2-dependent cancer in a subject, comprising a) measuring the amount of one or more miRNA selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29a-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-3p and miRNA 542-5p in a sample from the subject; b) comparing the amount of one or more miRNA measured in step a) to a reference value; c) finding a deviation or no deviation of the amount of one or more miRNA measured in step a) from the reference value; and d) attributing said finding of deviation or no deviation to a particular diagnosis and/or prognosis of HER2-dependent cancer in the subject.Type: GrantFiled: October 24, 2018Date of Patent: November 14, 2023Assignees: UNIVERSITÉ PARIS CITÉ, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: Sandrine Bourdoulous, Anaïs Domingot, Camille Faure
-
Patent number: 11814683Abstract: Some embodiments are directed to a prognostic method for determining whether a subject is at risk of having the CLAD, comprising: measuring the expression level of POU2AF1 or BLK in a biological sample obtained from the subject; comparing the expression level of POU2AF1 or BLK with a predetermined reference value and concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value.Type: GrantFiled: March 9, 2021Date of Patent: November 14, 2023Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique, Université de Nantes, Centre Hospitalier Universitaire de NantesInventors: Pierre-Joseph Royer, Antoine Magnan, Sophie Brouard, Richard Danger
-
H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer
Publication number: 20230349922Abstract: The present invention provides Histamine Receptor 2 antagonists and pharmaceutical compositions thereof for use in the treatment or prevention of liver disease, including liver fibrosis and hepato-biliary cancers. The present invention also relates to methods for identifying candidate compounds that are useful in the treatment or prevention of liver disease, including liver fibrosis and hepato-biliary cancers.Type: ApplicationFiled: August 11, 2021Publication date: November 2, 2023Applicants: Université de Strasbourg, Institut National de la Santé et de la Recherche MédicaleInventors: Thomas Baumert, Emilie Crouchet -
Publication number: 20230348934Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.Type: ApplicationFiled: March 6, 2023Publication date: November 2, 2023Applicants: Ecole Normale Superieure de Lyon, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Institut National de la Santé et de la Recherche Medicale (INSERM), Centre National de la Recherche ScientifiqueInventors: Caroline COSTA FEJOZ, Els Verhoeyen, François-Loîc Cosset, Ruben Bender, Christian Buchholz, Qi Zhou
-
Patent number: 11801400Abstract: A therapy apparatus for treating tissue by emission of focused ultrasound waves, including: a creation surface of a pressure field of focused ultrasound waves divided into at least N sectors having segments of asymmetrical concave curve with centres of curvature; centres of curvature asymmetrical to the extent where the centres of curvature are situated at different distances from the plane of symmetry or from at least one of the axis of symmetry and at different depths taken according to the axis of symmetry; the individual axes intersecting between the focal zones and the creation surface or beyond the focal zones such that the beams originating from the sectors intersect to create a focal coverage zone which is off-axis relative to the plane of symmetry or to the axis of symmetry; the sectors of this creation surface creating energy deposit zones with profiles corresponding to the focal coverage zones.Type: GrantFiled: April 1, 2021Date of Patent: October 31, 2023Assignees: EDAP TMS FRANCE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDECALE (INSERM), UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE LEON BERARDInventors: Marine Sanchez, David Melo De Lima, Jérémy Vincenot
-
Patent number: 11793864Abstract: This invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment, diagnosis or prognosis of skin diseases comprising the administration to a subject in need thereof of a therapeutically effective amount of a Serine protease inhibitor.Type: GrantFiled: December 12, 2018Date of Patent: October 24, 2023Assignees: DERMADIS SA, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventors: David Deperthes, Christoph Kundig, Alain Hovnanian, Celine Deraison
-
Patent number: 11793865Abstract: A composition including a supernatant obtained from co-culture of phagocytes with apoptotic cells. The composition is obtained by a) providing phagocytes, b) providing apoptotic cells, c) optionally washing the cells from step a) and b), d) co-culturing the cells of step a) and b), and e) separating the supernatant from the cells. The composition may be used in preventing or treating a pathological immune response.Type: GrantFiled: April 14, 2020Date of Patent: October 24, 2023Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ETABLISSEMENT FRANCAIS DU SANG, UNIVERSITE DE FRANCHE-COMTE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE BESANCONInventors: Sylvain Perruche, Philippe Saas, Francis Bonnefoy
-
Patent number: 11795144Abstract: The present invention concerns a compound having the following formula (I): wherein: A is in particular —N(R?a)—C(?O)—R, R?a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): X is in particular chosen from the group consisting of: —SO2—N(R?b)—, R?b being H or a (C1-C6)alkyl group, —N(R?b)—SO2—, R?b being H or a (C1-C6)alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of cancers, such as metastatic cancers.Type: GrantFiled: June 6, 2018Date of Patent: October 24, 2023Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, CHU NANTESInventors: Vincent Sauzeau, Gervaise Loirand, Jacques Lebreton, Arnaud Tessier, Agnès Quemener
-
Publication number: 20230330440Abstract: Devices and methods for reversibly stimulating neuronal cells in a subject. The devices include a module for generating ultrasounds at 4 MHz or more to stimulate neuronal cells expressing mechanosensitive channels with the ultrasounds. The methods include expressing mechanosensitive channels into neuronal cells and exposing the cells to ultrasounds at 4 MHz or more. Also, the use of the methods or devices for visual restoration in a subject.Type: ApplicationFiled: September 9, 2021Publication date: October 19, 2023Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Serge PICAUD, Sara CADONI, José-Alain SAHEL, Mickaël TANTER, Charlie DEMENE
-
Patent number: 11780934Abstract: It has been discovered that disrupting the stromal capsule restores a better vasculature/tumor perfusion and improve T cells infiltration inside the core of a melanoma. The invention relates to the use of drugs or immunoconjugates that target the transmembrane protease ADAM12 and deplete the cells that express it. Since ADAM12 protein is specifically expressed by stromal cells of the tumor stromal capsule and around vessels in models for prostate cancer, neuroendocrine pancreatic cancer and melanoma, an ADAM12 inhibitor is useful in anti-tumor therapies as an adjuvant. The invention encompasses methods, compositions, and kits containing ADAM12 inhibitors for use in the depletion of ADAM12+ stromal cells in cancer patient, particularly together with anti-tumor compounds and treatments.Type: GrantFiled: February 3, 2017Date of Patent: October 10, 2023Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventors: Lucie Peduto, Selene Di Carlo
-
Patent number: 11773163Abstract: The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.Type: GrantFiled: November 21, 2017Date of Patent: October 3, 2023Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE STRASBOURG, ETABLISSEMENT FRANçAIS DU SANG (EFS)Inventors: Pierre Mangin, Christian Gachet
-
Publication number: 20230306731Abstract: Method for the prediction of labels associated with a digital image, comprising a prediction phase consisting of: supplying the image to a segmentation neural network configured to predict a classification of the pixels of the image into a first set of classes; and supplying at least part of this classification to a classification neural network configured to predict a set of labels for said image, based on the classification P of the pixels; said segmentation and classification neural networks being determined by a learning phase comprising, for each image of a training set, the first and second steps; and determining a location of the background of said image, based on the classification of the pixels, and optimizing the weights of the neural networks according to a set of cost functions configured, by iteration, to maximize the quality of the set of labels as a function of labels previously established and associated with the image, and to maximize the probability of not predicting any label for the bacType: ApplicationFiled: July 21, 2021Publication date: September 28, 2023Applicants: UNIVERSITE BRESTBRETAGNE OCCIDENTALE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)Inventor: Gwenolé QUELLEC
-
Publication number: 20230303974Abstract: The present invention relates to an engineered immune cell defective for SOCS1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of SOCS1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.Type: ApplicationFiled: July 30, 2021Publication date: September 28, 2023Applicants: Institut Curie, Institut National de la Santé et de la Recherche MédicaleInventors: Laurie Menger, Silvia Menegatti, Sebastian Amigorena
-
Patent number: 11767333Abstract: The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea, atopic dermatitis, psoriasis and itch) caused by abnormally high levels of protease activity (particularly of serine proteases such as kallikreins). In addition, the invention relates to compositions containing the derivatives and processes for their preparation.Type: GrantFiled: May 6, 2022Date of Patent: September 26, 2023Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: John Liddle, Ann Louise Walker, Gemma Victoria White, Alexis Denis, Nerina Dodic, Marie-Hélène Fouchet, Anne Bouillot
-
Publication number: 20230293586Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.Type: ApplicationFiled: April 6, 2023Publication date: September 21, 2023Applicants: Assistance Publique - Hopitaux de Paris, Fondation Imagine - Institut des Maladies Génétiques, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Isabelle ANDRÉ, Marina CAVAZZANA, Kuiying MA, John TCHEN, Tayebeh-Shabi SOHEILI, Ranjita Devi MOIRANGTHEM
-
Publication number: 20230293478Abstract: The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: wherein W, X, Y and Z are as defined, for use in the treatment of Acute Myeloid Leukemia (AML).Type: ApplicationFiled: May 12, 2021Publication date: September 21, 2023Applicants: Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie, Peter MacCallum Cancer InstituteInventors: Raphaël RODRIGUEZ, Mark DAWSON, Sylvain GARCIAZ, Tatiana CANEQUE COBO
-
Publication number: 20230288403Abstract: An in vitro assay for inducing extracellular trap (ET) formation, including contacting immune cells, in in vitro culture or within a biological sample, with immobilized human polyvalent immunoglobulins; and to uses thereof, in particular in an in vitro method for screening a drug for its ability to modulate ET formation, in an in vitro method for assessing the susceptibility of a subject to ET formation, in an in vitro method for predicting the response of a subject to a modulator of ET formation, and in in vitro method for monitoring the response of a subject to an immunomodulator.Type: ApplicationFiled: February 10, 2023Publication date: September 14, 2023Applicants: Tridek-One Therapeutics, INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paris XIII, Université Paris CitéInventors: Giuseppina CALIGIURI, Antonino NICOLETTI, Thi Thu Trang TRAN